2.46
2.87%
0.02
前日終値:
$2.44
開ける:
$2.59
24時間の取引高:
88,620
Relative Volume:
1.11
時価総額:
$3.70M
収益:
-
当期純損益:
$-12.30M
株価収益率:
-0.3825
EPS:
-6.4313
ネットキャッシュフロー:
$-11.13M
1週間 パフォーマンス:
-4.20%
1か月 パフォーマンス:
-35.81%
6か月 パフォーマンス:
-53.60%
1年 パフォーマンス:
-71.64%
Palisade Bio Inc Stock (PALI) Company Profile
名前
Palisade Bio Inc
セクター
電話
(858) 704-4900
住所
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
PALI を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
PALI | 2.5198 | 3.70M | 0 | -12.30M | -11.13M | -6.4313 |
VRTX | 450.34 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.04 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 245.32 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.38 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Palisade Bio Inc (PALI) 最新ニュース
Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire
ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - The Manila Times
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Palisade Bio Inc (PALI) Quarterly 10-Q Report - Quartzy
Palisade Bio Reports Third Quarter 2024 Financial Results - GlobeNewswire
Palisade Bio Advances UC Drug Trial: Key Phase 1 Milestones & Patent Wins Boost Pipeline | PALI Stock News - StockTitan
Palisade Bio initiates phase 1 study of new UC drug - Investing.com
Palisade Bio initiates phase 1 study of new UC drug By Investing.com - Investing.com Australia
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) - The Manila Times
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights - The Manila Times
Palisade Bio Announces First Subject Dosed in Phase 1 - GlobeNewswire
Palisade Bio Launches Phase 1 Trial for Novel Ulcerative Colitis Drug PALI-2108 | PALI Stock News - StockTitan
Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World
Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com
Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK
HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times
Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com
Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting - The Manila Times
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World
Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia
Palisade Bio receives Health Canada nod for UC drug trial - Investing.com
Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World
Palisade Bio inks new deal with CEO Finley; terms disclosed By Investing.com - Investing.com Canada
Palisade Bio inks new deal with CEO Finley; terms disclosed - Investing.com India
Palisade Bio CEO Finley’s Revised Employment and Compensation Deal - TipRanks
Palisade submits CTA for PDE4 inhibitor prodrug for ulcerative colitis - BioWorld Online
PALI stock touches 52-week low at $3.3 amid market fluctuations - Investing.com UK
PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan
Palisade Bio Provides Update on Progress Toward Launch of - GlobeNewswire
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
Klea Holding Evaluates Generous Takeover Offer - TipRanks
The growth track for Kura Oncology Inc (KURA) has changed recently - SETE News
Potential Price Increase for Kulicke & Soffa Industries, Inc. (KLIC) After Recent Insider Activity - Knox Daily
Big Changes At Disney Animation: Jennifer Lee Steps Down And Jared Bush Steps In - mxdwn.com
116,268 Shares in Proficient Auto Logistics, Inc. (NASDAQ:PAL) Purchased by First Eagle Investment Management LLC - MarketBeat
Angelina Jolie overwhelmed by ‘beautiful feeling’ of motherhood - FemaleFirst
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Palisade Bio (NASDAQ:PALI) Stock Quotes, Forecast and News Summary - Benzinga
Proficient Auto Logistics (NASDAQ:PAL) Earns "Outperform" Rating from Barrington Research - MarketBeat
Jared Bush Taking Over Jennifer Lee’s Role As Walt Disney Animation Studios Chief Creative Officer - What's On Disney Plus
Palisade Bio Inc (PALI) 財務データ
収益
当期純利益
現金流量
EPS
Palisade Bio Inc (PALI) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Williams Donald Allen | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
340 |
0 |
340 |
Jones Mitchell Lawrence | Chief Medical Officer |
May 28 '24 |
Option Exercise |
0.00 |
4,290 |
0 |
4,313 |
Finley John David | CEO, CFO, Director |
May 28 '24 |
Option Exercise |
0.00 |
7,068 |
0 |
14,079 |
Williams Donald Allen | Director |
May 28 '24 |
Buy |
4.86 |
1,000 |
4,863 |
1,000 |
Finley John David | CEO, CFO, Director |
May 24 '24 |
Buy |
4.81 |
1,000 |
4,810 |
8,437 |
Jones Mitchell Lawrence | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
460 |
0 |
880 |
Finley John David | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
443 |
0 |
6,832 |
Finley John David | CEO, CFO, Director |
Mar 11 '24 |
Option Exercise |
0.00 |
5,558 |
0 |
96,849 |
Neal James R | Director |
Feb 09 '24 |
Option Exercise |
0.00 |
10,920 |
0 |
10,920 |
Csimma Cristina | Director |
Feb 08 '24 |
Option Exercise |
0.00 |
12,800 |
0 |
12,862 |
大文字化:
|
ボリューム (24 時間):